how InvestingPro’s Fair Value spotted Organon’s 69% gain potential

InvestingPro's Fair Value analysis identified Organon & Co. (NYSE:OGN) as a potentially undervalued opportunity in early February 2026, when the stock was trading at $8.00 per share. Despite the stock having declined over 40% from its highs, the analysis revealed a significantly undervalued stock with substantial upside potential.

By June 2026, Organon's stock had surged 68.75% to reach its target price of $13.50, validating the accuracy of the Fair Value analysis. The success of this investment case was attributed to several factors, including strong patent protection for its key product Nexplanon, a robust gross profit margin, and an impressive free cash flow yield.

Additionally, the company received positive news with Sun Pharma's $12 billion acquisition bid, an audit clearing the company of misconduct, and FDA approval for its tocilizumab biosimilar. These catalysts helped close the valuation gap and resulted in significant gains for investors who followed the Fair Value analysis recommendations.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.